Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-isopropyl-3-methyl-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinecarboxylate
2. Escor
3. Fr 34235
4. Fr-34235
5. Nivadil
1. 75530-68-6
2. Escor
3. Nivadil
4. Nivadipine
5. Fr-34235
6. Fk 235
7. Nivadip
8. Dl-nilvadipine
9. Fr 34235
10. Sk&f 102,362
11. Cl 287,389
12. Fk-235
13. Cl-287389
14. Nilvadipine (arc029)
15. Sk&f-102362
16. 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
17. 3-o-methyl 5-o-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
18. Cl-287,389
19. 0214fut37j
20. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
21. Skf-102362
22. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) Ester
23. Fr34235
24. Ncgc00167435-01
25. Sk&f-102,362
26. Nilvadipinum [latin]
27. Nilvadipino [spanish]
28. Nivaldipine
29. Nilvadipino
30. Nilvadipinum
31. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-methyl 5-(1-methylethyl) Ester
32. Nilvadipine [usan:inn:jan]
33. Arc029
34. Brn 3572609
35. Unii-0214fut37j
36. Nivadil (tn)
37. Mfcd00867065
38. Nilvadipine [mi]
39. Nilvadipine [inn]
40. Nilvadipine [jan]
41. Nilvadipine [usan]
42. Dsstox_cid_26624
43. Dsstox_rid_81774
44. Nilvadipine [mart.]
45. Dsstox_gsid_46624
46. Schembl33729
47. (+/-)-nilvadipine
48. Nilvadipine [who-dd]
49. Chembl517427
50. Dtxsid2046624
51. Chebi:31911
52. Faiifdpaeukbep-uhfffaoysa-
53. Gtpl10160
54. Nilvadipine (jp17/usan/inn)
55. Fk235
56. Hms3651j11
57. Hms3714a17
58. Hms3884f16
59. Bcp06007
60. Arc029;fr34235
61. Tox21_112439
62. Bdbm50103634
63. Akos015907577
64. Ccg-220648
65. Db06712
66. Ks-1303
67. Ncgc00167435-02
68. Ncgc00167435-03
69. Ncgc00167435-07
70. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 5-isopropyl 3-methyl Ester
71. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl-5-(1-methylethyl) Ester
72. 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
73. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
74. Ac-28326
75. Hy-14284
76. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
77. Cas-75530-68-6
78. Db-055963
79. Ft-0630839
80. N0899
81. S2721
82. Sw219572-1
83. D01908
84. Ab01566895_01
85. 530n686
86. A838445
87. Sr-01000872715
88. Q7037489
89. Sr-01000872715-1
90. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-
91. (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
92. 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid O3-methyl Ester O5-propan-2-yl Ester
93. 5-isopropyl 3-methyl (+)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
94. 5-isopropyl 3-methyl (-)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
95. 5-isopropyl3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Molecular Weight | 385.4 g/mol |
---|---|
Molecular Formula | C19H19N3O6 |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 385.12738533 g/mol |
Monoisotopic Mass | 385.12738533 g/mol |
Topological Polar Surface Area | 134 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 783 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the management of vasospastic angina, chronic stable angina and hypertension.
Nilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C - Cardiovascular system
C08 - Calcium channel blockers
C08C - Selective calcium channel blockers with mainly vascular effects
C08CA - Dihydropyridine derivatives
C08CA10 - Nilvadipine
Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?